N-acetyl-transferase phenotype and risk for preeclampsia.
OBJECTIVE
This study was undertaken to determine whether the N-acetyltransferase (NAT) phenotype contributes to the susceptibility for the development of preeclampsia.


METHODS
The NAT acetylator status was determined by measuring urinary caffeine metabolites in 134 nonpregnant women with a history of preeclampsia and in 109 control women with uncomplicated pregnancy. The chi(2) and logistic regression analyses were used for statistical evaluation of differences in acetylator status.


RESULTS
Significantly more fast acetylators were found among the women with a history of preeclampsia (46.3%) than among the controls (25.4%). Fast acetylators showed an odds ratio of 2.5 (95% CI 1.4-4.3) for preeclampsia. No differences in the acetylator status were found between women with a history of preeclampsia only and those with the HELLP syndrome as well.


CONCLUSIONS
The fast NAT acetylator status, which may result in altered NAT detoxification capacity, is associated with preeclampsia.
Zusterzeel
Petra L M
PL
Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
te Morsche
René H M
RH
Raijmakers
Maarten T M
MT
Roes
Eva Maria
EM
Peters
Wilbert H M
WH
Steegers-Theunissen
Régine P M
RP
Steegers
Eric A P
EA
D000328:Adult; D001191:Arylamine N-Acetyltransferase / Q000235:genetics*; D002110:Caffeine / Q000378:metabolism / Q000652:urine; D005260:Female; D020022:Genetic Predisposition to Disease; D017359:HELLP Syndrome / Q000235:genetics; D006801:Humans; D010641:Phenotype; D011225:Pre-Eclampsia / Q000235:genetics*; D011247:Pregnancy; D012907:Smoking / Q000235:genetics / Q000378:metabolism
D002110:Caffeine; D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human